What one share of Coya Therapeutics holds
We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (“Tregs”). Tregs are a subpopulation of T-lymphocytes consisting of CD4+CD25high hFOXP3+ cells that suppress inflammatory responses.
Coya Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.40 |
|---|---|
| Profit | −$1.09 |
| Cash and investments | $1.84 |
| Book value | $1.84 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$1.89 | — | — | — | $1.41 |
| 2022 | $0.00 | −$4.73 | — | — | — | −$3.24 |
| 2023 | $0.59 | −$0.79 | — | — | — | $2.47 |
| 2024 | $0.23 | −$0.98 | — | — | — | $2.37 |
| 2025 | $0.47 | −$1.27 | — | — | — | $2.06 |
Common questions about Coya Therapeutics
How much does one share of Coya Therapeutics earn?
Over the last 12 months, Coya Therapeutics lost $1.09 for each share on $0.40 of sales.
Does Coya Therapeutics pay a dividend?
Coya Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Coya Therapeutics’s book value per share?
Coya Therapeutics’s book value is $1.84 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Coya Therapeutics have?
Each share of Coya Therapeutics has $1.84 of cash and investments, as of June 30, 2026.
Has Coya Therapeutics bought back shares?
Coya Therapeutics’s share count rose about 546% from 2021 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.